ORIGINAL_ARTICLE In vitro maturation is a highly effective method for achieving mature. Oocytes to treat infertility based on in vitro methods (IVF-ICSI). This technique is effective for treating women who suffer from polycystic ovary syndrome (PCO) and cancer. Immature oocytes were obtained from 6-8 weeks old NMRI mice, 48 hours after intraperitoneal injection of 7.5 units of PMSG. The collected oocytes were divided into two groups: 1.The control group including the base medium 2. The experimental group including base medium supplemented with 25% human follicular fluid.100 oocytes (50 GV oocytes and 50 MI oocytes) were considered for each group. The oocytes of each group were cultured in incubator with 5% CO2 at 37 ºC for 24 hours. Although the resumption of meiosis in the experimental group was more than the control group (44 and 33%, respectively), the difference was not statistically significant (PV>0.05). Moreover, among immature oocytes, the development of GV oocytes to mature oocyte was more than MI oocytes. 50%, 38% of GV oocytes and 28%, 38% of MI oocytes, respectively in the experimental and control groups reached to mature oocyte. Results of the present study demonstrated that a higher percentage of immature oocytes in the experimental group matured in to MII oocytes. It seems that adding follicular fluid to the culture media has positive effects on oocyte maturation. Moreover, GV oocytes are more capable to reach in MII stage compared with MI oocytes in vitro. http://ibbj.org/article-1-222-en.pdf 2021-05-19 0 0 In vitro maturation follicular fluid Germinal Vesicle Seyede Zahra Talebian Moghadam 1 Department of Biology, Qaemshahr Branch, Islamic Azad University, Qaemshahr, Iran AUTHOR Seyed Gholam Ali Jorsaraei alijorsara@yahoo.com 2 Infertility and Reproductive Health Research Center, Health Research Institute, Babol University of Medical Science, Babol, Iran AUTHOR https://orcid.org/0000-0001-5440-6792 Ramzan Khanbabaei 3 Department of Biology, Qaemshahr Branch, Islamic Azad University, Qaemshahr, Iran AUTHOR https://orcid.org/0000-0003-0276-4672 Maryam Gholamitabar Tabari 4 Health Reproductive Research Center, Sari Branch, Islamic Azad University, Sari, Iran AUTHOR https://orcid.org/0000-0003-2525-6881 Ali Asghar Ahmadi 5 North Research Center, Pasteur Institute of Iran, Amol, Iran AUTHOR https://orcid.org/0000-0003-2286-534X

ORIGINAL_ARTICLE Background: Diabetes mellitus is a chronic metabolic disorder characterized by defect in insulin secretion and action resulting in hyperglycemia. Diabetic patients have deranged body metabolisms particularly for lipids which may result in abnormal levels of serum levels of lipids. Methods: The aim of this study is to find any possible correlation between the the glycosylated hemoglobin and the lipid profile in patients with type 2 diabetes mellitus in Duhok city. A total number of 235 patients with type 2 diabetes were included. Results: The mean age was 56.19 years, and females constituted 73.2%. The mean duration of diabetes was 101.30 months, and the mean level of HbA1c was 8.0297 %. About 58.30% had good glycemic control, 28.51 % had poor control, and 13.19% had excellent control. The mean level of the serum cholesterol was normal (180.63 mg/dl), and the mean level of serum triglycerides were elevated (188.46 mg/dl), the mean level of the LDL was elevated (102.07 mg/dl), and the mean HDL level was normal (47.30 mg/dl). There was a significant correlation between the mean level of HbA1c and LDL levels (P value 0.005) while the correlation was not significant for other types of serum lipids such as triglycerides, cholesterol, and HDL (P values 0.879, 0.091, and 0.253) respectively, Conclusion: Elevated glycosylated hemoglobin may be an indicator of derangement of the lipid metabolism and elevated levels of serum lipid profiles which indirectly may indicate high risk factor and as a predictor for increased risk of end stage vascular disease. http://ibbj.org/article-1-257-en.pdf 2021-02-17 0 0 Glycosylated hemoglobin HbA1C Diabetes mellitus Lipid profile LDL. Jihan Mustafa jihan.ahmed@uod.ac 1 Department of chemistry, College of Science, University of Duhok, Kurdistan Region, Iraq. AUTHOR Ayad Ahmad ayad.mohammed@uod.ac 2 Department of Surgery, College of Medicine, University of Duhok, Kurdistan Region, Iraq. AUTHOR

OTHERS_CITABLE                  Fabry disease is a rare, inherited disease with lack of the enzyme alpha-galactosidase A (α-Gal)  in the cells of the body that participates in the breakdown of fat. The disease begins in early childhood, progresses slowly throughout life and results in severe damage of the kidneys, heart and central nervous system. The disease is life-threatening and if left untreated, death occurs in the fourth or fifth decade of life. The development of the disease and the onset of symptoms are entirely individual: they are unpredictable and often depend on hereditary predisposition. Very often a child or adult with these symptoms visits 7 to 10 different specialists before being properly diagnosed, although the fact that early diagnosis is the key of successful treatment. Early recognition of a person  with Morbus Fabry is very important, because as soon as patients start to be treated with appropriate therapy the damage of the internal organs is prevented. Enzyme replacement therapy (ERT) as a specific therapy for this disease was introduced in 2001 and is obtained by use of in vitro prepared alpha-galactosidase A. The  interdisciplinary team of dental specialists in collaboration with medical doctors must be included in the dental  treatment of patients with Fabry disease. They have to work together in order to improve oral health-related quality of life of patients with Fabry disease.                 Fabry disease is a rare, inherited disease with lack of the enzyme alpha-galactosidase A (α-Gal)  in the cells of the body that participates in the breakdown of fat. The disease begins in early childhood, progresses slowly throughout life and results in severe damage of the kidneys, heart and central nervous system. The disease is life-threatening and if left untreated, death occurs in the fourth or fifth decade of life. The development of the disease and the onset of symptoms are entirely individual: they are unpredictable and often depend on hereditary predisposition. Very often a child or adult with these symptoms visits 7 to 10 different specialists before being properly diagnosed, although the fact that early diagnosis is the key of successful treatment. Early recognition of a person  with Morbus Fabry is very important, because as soon as patients start to be treated with appropriate therapy the damage of the internal organs is prevented. Enzyme replacement therapy (ERT) as a specific therapy for this disease was introduced in 2001 and is obtained by use of in vitro prepared alpha-galactosidase A. The  interdisciplinary team of dental specialists in collaboration with medical doctors must be included in the dental  treatment of patients with Fabry disease. They have to work together in order to improve oral health-related quality of life of patients with Fabry disease.v                 Fabry disease is a rare, inherited disease with lack of the enzyme alpha-galactosidase A (α-Gal)  in the cells of the body that participates in the breakdown of fat. The disease begins in early childhood, progresses slowly throughout life and results in severe damage of the kidneys, heart and central nervous system. The disease is life-threatening and if left untreated, death occurs in the fourth or fifth decade of life. The development of the disease and the onset of symptoms are entirely individual: they are unpredictable and often depend on hereditary predisposition. Very often a child or adult with these symptoms visits 7 to 10 different specialists before being properly diagnosed, although the fact that early diagnosis is the key of successful treatment. Early recognition of a person  with Morbus Fabry is very important, because as soon as patients start to be treated with appropriate therapy the damage of the internal organs is prevented. Enzyme replacement therapy (ERT) as a specific therapy for this disease was introduced in 2001 and is obtained by use of in vitro prepared alpha-galactosidase A. The  interdisciplinary team of dental specialists in collaboration with medical doctors must be included in the dental  treatment of patients with Fabry disease. They have to work together in order to improve oral health-related quality of life of patients with Fabry disease.                 Fabry disease is a rare, inherited disease with lack of the enzyme alpha-galactosidase A (α-Gal)  in the cells of the body that participates in the breakdown of fat. The disease begins in early childhood, progresses slowly throughout life and results in severe damage of the kidneys, heart and central nervous system. The disease is life-threatening and if left untreated, death occurs in the fourth or fifth decade of life. The development of the disease and the onset of symptoms are entirely individual: they are unpredictable and often depend on hereditary predisposition. Very often a child or adult with these symptoms visits 7 to 10 different specialists before being properly diagnosed, although the fact that early diagnosis is the key of successful treatment. Early recognition of a person  with Morbus Fabry is very important, because as soon as patients start to be treated with appropriate therapy the damage of the internal organs is prevented. Enzyme replacement therapy (ERT) as a specific therapy for this disease was introduced in 2001 and is obtained by use of in vitro prepared alpha-galactosidase A. The  interdisciplinary team of dental specialists in collaboration with medical doctors must be included in the dental  treatment of patients with Fabry disease. They have to work together in order to improve oral health-related quality of life of patients with Fabry disease. http://ibbj.org/article-1-259-en.pdf 2021-02-17 0 0 Fabry disease Oral manifestations Rare diseases Interdisciplinary dentistry. Vesna Ambarkova vesna.ambarkova@gmail.com 1 University St. Cyril and Methodius, Faculty of Dental Medicine, Department of Paediatric and Preventive Dentistry, Skopje, Republic of North Macedonia AUTHOR Arjeta Sulejmani arjetasul@gmail.com 2 kindergarten OJUDG Mladost-Tetovo AUTHOR Tina Krmzova tina.krmzova@gmail.com 3 AUTHOR Zoran Nonkulovski zoran_non@yahoo.com 4 AUTHOR

ORIGINAL_ARTICLE Abstract: Preeclampsia contributes significantly to maternal & perinatal morbidity and mortality. Objective: To study maternal & fetal outcome in preeclampsia. Method: Case records of 168 women with preeclampsia, out of which 58 had severe preeclampsia were analysed. This retrospective observational study was conducted at B.J. government medical college, Pune, during period of 1st March 2020 to 30th June 2020. Result: Incidence of PE was 6.43.  Among study group 70% were primigravida & nearly 70% were >37 weeks of gestation. 15 (8.9%) patients developed eclampsia, 6(3.5%) developed abruptio placentae, 5(2.9%) had HELLP syndrome. PPH was noted in 22% cases. Prematurity, LBW & stillbirth was noted in 54(32%), 59(35%) and 7(4%) cases respectively. 54% Cases delivered by caesarean section. The adverse maternal outcome includes PPH, eclampsia, abruptio placenta, while for fetus prematurity and LBW which increased fetomaternal morbidity in patients of preeclampsia. Conclusion:     Although it is not possible to prevent PE & its morbidity, antenatal screening for early detection & timely intervention will help to improve pregnancy outcome. http://ibbj.org/article-1-267-en.pdf 2022-01-12 0 0 Preeclampsia HELLP Syndrome Eclampsia maternal morbidity Swati Gurav swati.gurav2009@gmail.com 1 Assistant professor AUTHOR Uma Wankhede drumawankhede@rediffmail.com 2 Professor and head of department HOD AUTHOR

ORIGINAL_ARTICLE This study assessed the seroepidemiology of Toxoplasma gondii, Hepatitis B Virus, and their co-infection infection in women of child-bearing age in communities in Osun State, Nigeria. The study also determines the factors that facilitate the organisms among the studied groups and possible interaction between the prevalence of infection and the risk factors. These were done with a view to providing baseline information on the mode of T. gondii and Hepatitis B Virus transmission.       Sera were analyzed for the presence of IgG and IgM antibodies against T. gondii by a commercially available enzyme linked immunosorbent assay (ELISA) kit (Demeditec Diagnostics GmbH, Germany) conducted according to the manufacturer’s instructions. The optical densities of wells were measured by a photometer at a wavelength of 450 nm and the detection of hepatitis B surface antigen (HBsAg) was done using rapid immunochromatographic (IC) tests which are in cassette form. Determination of the blood groups of the donors was done using commercially prepared Anti sera A, B, AB, and anti D that determine the Rhesus blood group.       The overall prevalence of T. gondii among the women of child-bearing age in selected six communities in Osun state was 74.2%, while the overall prevalence of Hepatitis B virus among the women was 4.3% and co-infection of T. gondii and Hepatitis B virus was 3.6%. The prevalence of T. gondii was lowest (57.8%) among women from Ile Ife, a peri-urban community and highest (100%) in women residing in Alajue, a rural community. The prevalence of T. gondii infection was significantly higher (P= 0.001) among Islamic women (85.9%) than in Christian women (68.2%) while the prevalence of Hepatitis B virus (5.0%) and co-infection of T. gondii and Hepatitis B virus (3.8%) was higher among Christianity. The highest prevalence of (83.6%) was recorded in women with primary education while the lowest of (58.7%) was recorded in women with tertiary education (p =0.037). The highest prevalence of T. gondii (78.5%) was recorded in women that reside in rural area and the lowest (67.5%) was recorded in women that reside in peri-urban area (p=0.016) and also the prevalence of Hepatitis B virus (5.9%) and co-infection of T. gondii and Hepatitis B virus (4.6%) was higher in rural area, The highest prevalence of 74.4% of T. gondii was recorded in women with one miscarriage while the lowest value of 73.3% was recorded in women with two miscarriages and the highest prevalence of Hepatitis B Virus infection of 5.7% was recorded in women with one miscarriage while the lowest prevalence of 4.7% was recorded in women with no miscarriage.     The highest prevalence of 100.0% of T. gondii and 7.1% of Hepatitis B Virus infection was recorded in women with pregnancy while the lowest of 13.6% and 4.2% was recorded in women without pregnancy for both respectively.           The study concluded that there was a high prevalence of T. gondii infection (74.2%) and also implicates Hepatitis B virus (4.3%) and co-infection of both (3.6%) in the studied population. The high prevalence of T. gondii recorded among women of child-bearing age in the study was highly facilitated by the drinking of water from various sources in the study area. Hence, there is a need for health education and create awareness of the disease and its transmission to women of reproductive age group in general and pregnant women in particular to reduce the risk of T. gondii and Hepatitis B virus in pregnant women. http://ibbj.org/article-1-269-en.pdf 2022-01-12 0 0 SEROPREVALENCE CO- INFECTION Toxoplasma gondii Hepatitis B Virus WOMEN CHILD-BEARING AGE NIGERIA Olarinde Olaniran olarinde71@gmail.com 1 Obafemi Awolowo University AUTHOR https://orcid.org/0000-0003-4239-408X Ayobami Esther Awoyeni ayobams10@yahoo.com 2 Obafemi Awolowo University AUTHOR Oluwayemisi, Olanrewaju Olaniran Oluwayemisi866@gmail.com 3 Obafemi Awolowo University Teaching Hospital complex AUTHOR patience, Ngozi Adenekan ngadenekan@gmail.com 4 Obafemi Awolowo University Teaching Hospital complex AUTHOR Daniel Adegoke dangokehillson@gmail.com 5 Obafemi Awolowo University Teaching Hospital complex AUTHOR samuel Oladosu samoladosu@gmail.com 6 Obafemi awolowo University Health Center AUTHOR